- What is the Population Count?
- What is the Land Area?
- What is the Percent who did not finish the 9th grade?
- What is the Median Earnings?
- What is the Number of Employees?
- What is the Crime incident count?
- What is the Population Rate of Change?
- What is the Water Area?
- What is the High School Graduation Rate?
- What is the Median Female Earnings?
The population density of Reading, PA was 8,925 in 2018.
Geographic and Population Datasets Involving Reading, PA
- API data.pa.gov | Last Updated 2022-01-21T16:34:26.000Z
This dataset contains aggregate death data at the state and county level for Pennsylvania residents. The data are displayed by county, date, death counts, averages, rates based on population. Pennsylvania statewide numbers are listed with Pennsylvania named as the county for the statewide totals. Do not add up the entire file (all rows) or counts will be duplicated. Data will be updated between 9-11 am every day.
- API data.pa.gov | Last Updated 2022-01-21T16:34:28.000Z
This dataset contains aggregate COVID-19 case counts and rates by date of first report for all counties in Pennsylvania and for the state as a whole. Counts include both confirmed and probable cases as defined by the Council of State and Territorial Epidemiologists (CSTE). At present, a person is counted as a case only once. Note that case counts by date of report are influenced by a variety of factors, including but not limited to testing availability, test ordering patterns (such as day of week patterns), labs reporting backlogged test results, and mass screenings in nursing homes, workplaces, schools, etc. Case reports received without a patient address are assigned to the county of the ordering provider or facility based on provider zip code. Cases reported with a residential address that does not match to a known postal address per the commonwealth geocoding service are assigned to a county based on the zip code of residence. Many zip codes cross county boundaries so there is some degree of misclassification of county. All counts may change on a daily basis due to reassignment of jurisdiction, removal of duplicate case reports, correction of errors, and other daily data cleaning activities. Downloaded data represents the best information available as of the previous day. <br> Data will be updated between 9-11 am every day.
- API data.pa.gov | Last Updated 2022-01-20T16:34:23.000Z
This dataset contains aggregate data of COVID vaccines administered to citizens based on county of residence. Data includes counts of individuals who received a vaccine dose that provides partial coverage against the disease and counts of individuals that received a vaccine dose that provides full coverage against the disease. Suppression applies for quantities less than 5. Data only includes information reported to PA-SIIS, the Pennsylvania Statewide Immunization Information System.
Emergency Department (ED) Visits for Overdose Identified Through Syndromic Surveillance Quarter 3 2016 - Current Quarterly County Healthdata.pa.gov | Last Updated 2020-05-28T18:04:43.000Z
View quarterly trends in overdose rates for Any Drug Overdoses, Any Opioid Overdoses and Heroin Overdoses at the state and county level. Please see Overdose Data Technical Notes for additional details: : https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx
- API data.pa.gov | Last Updated 2018-11-05T16:26:18.000Z
County level educational attainment data on the adult working aged population (25-64) by age range and gender. Data is sourced from the US Census Bureau’s American Community Survey (ACS) 5-year estimates allowing for increased statistical reliability of the data for less populated areas and small population subgroups. More information here - https://www.census.gov/data/developers/data-sets/acs-5year.html
- API bronx.lehman.cuny.edu | Last Updated 2012-10-21T14:06:17.000Z
2010 Census Data on population, pop density, age and ethnicity per zip code
Counts and Rates of New HIV Diagnoses Among Individuals Using Injection Drugs January 2016 - Current Monthly County & Statewide Healthdata.pa.gov | Last Updated 2021-04-20T18:42:52.000Z
This indicator includes the count and rate of new HIV diagnoses among individuals using injection drugs per 100,000 individuals estimated to have Drug Use Disorder.
- API data.pa.gov | Last Updated 2021-12-22T18:58:01.000Z
Aggregate counts of partially and fully COVID-19 vaccinated people as reported through the Pennsylvania Statewide Immunization Information System (PA SIIS), along with percent of population calculations for the PA Senate Districts. To assign districts, records were geocoded to the street address or to ZIP code centroid when street addressed failed. Aggregate case counts of 1 through 4 for each district are suppressed and displayed as a null value. District value displayed as null when for records that could not be allocated to a district. Note: Pennsylvania residents who receive a COVID vaccine from a clinic in Philadelphia County, or received a vaccination from a federal facility (such as a veterans hospital or federal prison), or who received a vaccination in another state are not included in this map due to separate reporting requirements. Percentages are based on total population estimates (including children) from the US Census Bureau for each legislative district. For more information, please view the technical notes on the COVID-19 Dashboard.
- API data.pa.gov | Last Updated 2021-09-28T14:08:20.000Z
View quarterly trends in opioid dispensation data for all Schedule II-V opioids. Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx More information from U.S. Department of Justice https://www.deadiversion.usdoj.gov/schedules/ Schedule I Controlled Substances Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4-methylenedioxymethamphetamine ("Ecstasy"). Schedule II/IIN Controlled Substances (2/2N) Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence. Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone. Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®). Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital. Schedule III/IIIN Controlled Substances (3/3N) Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence. Examples of Schedule III narcotics include: products containing not more than 90 milligrams of codeine per dosage unit (Tylenol with Codeine®), and buprenorphine (Suboxone®). Examples of Schedule IIIN non-narcotics include: benzphetamine (Didrex®), phendimetrazine, ketamine, and anabolic steroids such as Depo®-Testosterone. Schedule IV Controlled Substances Substances in this schedule have a low potential for abuse relative to substances in Schedule III. Examples of Schedule IV substances include: alprazolam (Xanax®), carisoprodol (Soma®), clonazepam (Klonopin®), clorazepate (Tranxene®), diazepam (Valium®), lorazepam (Ativan®), midazolam (Versed®), temazepam (Restoril®), and triazolam (Halcion®). Schedule V Controlled Substances Substances in this schedule have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. Examples of Schedule V substances include: cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams (Robitussin AC®, Phenergan with Codeine®), and ezogabine.
- API data.pa.gov | Last Updated 2021-09-10T19:18:48.000Z
View quarterly trends in Risky Prescribing Measures, including: o Number/Rate of Individuals Seeing 5+ Prescribers and 5+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals Seeing 4+ Prescribers and 4+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals Seeing 3+ Prescribers and 3+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals with an Average Daily MME >50, >90 or >120: Average Daily MME is calculated as the sum of the total MME on each day in a time period based on all prescriptions an individual has filled divided by the number of days in the prescription(s). Measures include the number and rate of individuals prescribed greater than 50 MME per day, greater than 90 MME per day, or greater than 120 MME per day and is based on the patient’s county of residence. o Number/Rate of Individuals with Overlapping Opioid/Benzodiazepine Prescriptions: Number of individuals receiving overlapping opioid and benzodiazepine prescriptions during a given quarter. This measure is based on the patients’ county of residence. o Number/Rate of Individuals with > 30 Days of Overlapping Opioid/Benzodiazepine Prescriptions: Number and rate of individuals receiving overlapping opioid and benzodiazepine prescriptions for 30 days or more during a given quarter using state/county populations as denominators. This measure is based on the patients’ county of residence. Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx